Skip to main navigation Skip to search Skip to main content

Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma

  • HALO 109-301 Investigators
  • KU Leuven
  • University of California at San Francisco
  • Scripps Clinic
  • Seoul National University
  • IRCCS Istituto Europeo di Oncologia - Milano
  • Vall d'Hebron Institute of Oncology
  • National Institute of Oncology
  • Université Paris Cité
  • Cedars-Sinai Medical Center
  • Columbia University
  • Veterans General Hospital-Taipei
  • National Yang Ming Chiao Tung University
  • University of Washington
  • Centre Léon Bérard
  • University of Kansas
  • Ludwig Maximilian University of Munich
  • Hull University Teaching Hospitals NHS Trust
  • University of Pittsburgh
  • Generalitat de Catalunya
  • University of Michigan, Ann Arbor
  • Johns Hopkins University
  • Yale University
  • Centre régional de lutte du cancer Val d'Aurelle
  • New York University
  • Halozyme Therapeutics, Inc.
  • Beth Israel Deaconess Medical Center

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science